NPRL2 Inhibitors
NPRL2 inhibitors belong to a distinct chemical class of compounds that are known for their specific interaction with the NPRL2 protein. The NPRL2 protein, along with its binding partner NPRL3, constitutes a crucial component of the GATOR1 protein complex, which plays a fundamental role in the regulation of cellular nutrient sensing and metabolism. The GATOR1 complex functions as a negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1), a critical signaling pathway involved in cell growth, proliferation, and autophagy.
By inhibiting NPRL2, these compounds modulate the activity of the GATOR1 complex, leading to altered mTORC1 signaling. Consequently, NPRL2 inhibitors may impact various cellular processes, including protein synthesis, nutrient uptake, and cellular homeostasis. Due to the intricate role of mTORC1 in many cellular functions, NPRL2 inhibitors hold significant promise as valuable research tools for investigating the underlying mechanisms of nutrient sensing and metabolism regulation. Their unique ability to selectively target NPRL2 further contributes to their relevance in understanding cellular signaling pathways and unlocking new insights into various physiological and pathological processes. As researchers delve deeper into the functions and interactions of NPRL2 inhibitors, the understanding of cellular signaling networks could be enhanced, ultimately contributing to the advancement of basic science knowledge in the field of cell biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin (Sirolimus) directly binds to and inhibits the mTORC1 complex, which indirectly leads to the inhibition of NPRL2's role in mTORC1 signaling. This inhibition occurs as rapamycin disrupts the mTORC1 pathway, affecting the cellular processes regulated by NPRL2 within this pathway. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus (Afinitor), a rapamycin analog, inhibits mTORC1 by binding to the same intracellular receptor as rapamycin, leading to a decrease in the activity of mTORC1. This action indirectly affects NPRL2's regulatory functions in the mTORC1 signaling pathway, inhibiting processes that NPRL2 influences through mTORC1. | ||||||
Ridaforolimus | 572924-54-0 | sc-212783 | 5 mg | $248.00 | 1 | |
Ridaforolimus (Deforolimus) targets mTORC1 for inhibition, which indirectly impacts the NPRL2-mediated regulation of mTORC1 activity. By inhibiting mTORC1, ridaforolimus affects the cellular processes that NPRL2 influences through its role in the mTORC1 signaling pathway. | ||||||
OSI-027 | 936890-98-1 | sc-364557 sc-364557A | 10 mg 50 mg | $437.00 $1186.00 | 1 | |
OSI-027, by inhibiting both mTORC1 and mTORC2, indirectly affects NPRL2's regulatory actions within the mTORC1 pathway, disrupting the processes NPRL2 regulates through mTORC1. | ||||||
AZD2014 | 1009298-59-2 | sc-364420 | 5 mg | $303.00 | 2 | |
AZD2014, as a dual inhibitor of mTORC1/2, indirectly inhibits NPRL2's involvement in mTORC1 signaling by targeting the mTOR complexes, affecting the cellular functions that NPRL2 influences through mTORC1. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) and INK128 (TAK-228), by inhibiting both mTORC1 and mTORC2, indirectly disrupt NPRL2's regulatory role within the mTORC1 pathway, impacting the cellular responses controlled by NPRL2 in relation to mTORC1 activity. | ||||||